Suzhou Zelgen Biopharmaceuticals Hits Day High with 7.24% Surge

Suzhou Zelgen Biopharmaceuticals Co., Ltd. has experienced a significant uptick in its stock performance, gaining 7.24% on March 10, 2026. The stock reached an intraday high of CNY 86.90, marking a notable achievement for the company within the pharmaceuticals and biotechnology sector. In terms of performance metrics, Suzhou Zelgen's one-week performance stands at 12.07%, significantly outperforming the China Shanghai Composite, which recorded a mere 0.01% during the same period. However, the company has faced challenges over the longer term, with a one-month decline of 10.58% and a year-to-date drop of 7.44%. Despite these fluctuations, the company has shown resilience, reporting positive results for the last four consecutive quarters, with net sales peaking at CNY 217.79 million. Additionally, the raw material costs have decreased by 9.19% year-over-year, contributing to improved operational efficiency as indicated by a debtor turnover ratio of 4.49 times. Overall, while Suzhou Zelgen Biopharmaceuticals has made strides in the short term, its long-term growth prospects remain a topic of scrutiny within the market.